Last reviewed · How we verify
CD34-positive cells
At a glance
| Generic name | CD34-positive cells |
|---|---|
| Sponsor | Losordo, Douglas, M.D. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Clonal Architecture of ASXL1-mutated Myelofibrosis (NA)
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (PHASE1, PHASE2)
- OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study (NA)
- Compassionate Access of the Miltenyi Device for CD34+ Cell Selection (NA)
- HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (PHASE2)
- BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS (PHASE1, PHASE2)
- Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD34-positive cells CI brief — competitive landscape report
- CD34-positive cells updates RSS · CI watch RSS
- Losordo, Douglas, M.D. portfolio CI